Cellectis SA (NASDAQ:CLLS) Q1 2023 Earnings Conference Call May 5, 2023 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Co-Founder, CEO & Director Mark Frattini - SVP, Clinical Sciences & Chief Medical Officer Bing Wang - CFO Conference Call Participants Gena Wang - Barclays Bank Yigal Nochomovitz - Citigroup Anoumid Vaziri - Goldman Sachs Group Dev Prasad - Jefferies Hartaj Singh - Oppenheimer Jack Allen - Robert W. Baird & Co. Ingrid Gafanhao - Kempen Silvan Tuerkcan ...

Exhibit 99.1 PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three- and six-month periods ended June 30, 2023, included herein, have been prepared in accordance with International Accounting Standard 34 (“IAS 34”)– Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”). The consolidated financial statements are presented in U.S. dollars. All references in this interim report to “$” and “U.S. dollars” mean U.S. dollars and all referen ...

EXHIBIT 99.1 Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that preclinical data exploring purposeful armoring of CAR ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Cellectis S.A. (NASDAQ:CLLS) Q4 2022 Earnings Conference Call March 9, 2023 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Chief Executive Officer Bing Wang - Chief Financial Officer Mark Frattini - Chief Medical Officer Conference Call Participants Dev Prasad - Jefferies Gena Wang - Barclays Andrea Tan - Goldman Sachs Jack Allen - Baird Hartaj Singh - Oppenheimer & Company David Dai - SMBC Yanan Zhu - Wells Fargo Securities Brooke Schuster - William Blair Silvan Tuer ...

EXHIBIT 99.1 Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results Entered into a €40 million credit facility with the European Investment Bank and closed an approximatively $25 million follow-on equity offering to support Cellectis’ research, development and innovation activities Positive preliminary clinical data from Phase 1 BALLI-01 study (evaluating UCART22) for patients with r/r B-cell ALL presented in a Live Webcast; First patient dosed with UCART22 produc ...

Cellectis S.A. (NASDAQ:CLLS) Q3 2022 Earnings Conference Call November 4, 2022 8:00 AM ET Operator Company Participants | --- | |------------------------------------------| | | | Arthur Stril - Chief Business Officer | | Andre Choulika - Chief Executive Officer | | Mark Frattini - Chief Medical Officer | | Bing Wang - Chief Financial Officer | | Conference Call Participants | | Gena Wang - Barclays | | Jack Allen - Baird | | Yigal Nochomovitz - Citigroup | | Salveen Richter - Goldman Sachs | | David Dai - S ...

Cellectis S.A. (NASDAQ:CLLS) Q2 2022 Earnings Conference Call August 5, 2022 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Chief Executive Officer Bing Wang - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Ashiq Mubarack - Citi Hartaj Singh - Oppenheimer Jack Allen - Baird David Dai - SMBC Silvan Tuerkcan - JMP Securities Nicolas Abbott - Wells Fargo Operator Good morning, everyone, and welcome to the Cellectis Second Quarter 2020 Earnings ...

| --- | --- | --- | --- | |----------------------------------------|-------|-------|-------| | | | | | | | | | | | Commitment to a Cure | | | | | | | | | | Corporate Presentation May 2022 | | | | | | | | | | NASDAQ: CLLS EURONEXT GROWTH: ALCLS.PA | | | | | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Cellectis S.A. (NASDAQ:CLLS) Q1 2022 Earnings Conference Call May 13, 2022 8:00 AM ET Â Company Participants | --- | --- | --- | |-------|-------|-------------------------------------------| | | | | | | | Arthur Stril - Chief Business Officer | | | | Andre Choulika - Chief Executive Officer | | | | Carrie Brownstein - Chief Medical Officer | | | | Bing Wang - Chief Financial Officer | | | | Conference Call Participants | | | | Gena Wang - Barclays | | | | Yigal Nochomovitz - Citigroup | | | | Kelly Shi - Je ...